Several case-control studies have reported that PD patients carrying severe GBA1 variants compared to carriers of mild or risk variants, present with a more severe clinical phenotype characterised by faster progression, and worse psychiatric and cognitive dysfunction, worsened by interventions such as DBS4,7–10. This evidence concerns the gene GBA1 and Parkinson disease.